MA29274B1 - Constructions d'acide nucleique - Google Patents
Constructions d'acide nucleiqueInfo
- Publication number
- MA29274B1 MA29274B1 MA30172A MA30172A MA29274B1 MA 29274 B1 MA29274 B1 MA 29274B1 MA 30172 A MA30172 A MA 30172A MA 30172 A MA30172 A MA 30172A MA 29274 B1 MA29274 B1 MA 29274B1
- Authority
- MA
- Morocco
- Prior art keywords
- nucleic acid
- hcmv
- sequence
- immediate early
- chimeric promoter
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UNE CONSTRUCTION D'ACIDE NUCLÉIQUE COMPORTANT UNE SÉQUENCE DE PROMOTEUR CHIMÈRE ET UN SITE DE CLONAGE POUR L'INSERTION D'UNE SÉQUENCE DE CODAGE EN LIAISON FONCTIONNELLE AVEC LE PROMOTEUR CHIMÈRE, LADITE SÉQUENCE DU PROMOTEUR CHIMÈRE COMPRENANT: (A) UNE SÉQUENCE PROMOTEUR PRÉCOCE IMMÉDIATE HCMV; (B) L'EXON 1 ET AU MOINS UNE PARTIE DE L'EXON 2 DU GÈNE PRÉCOCE IMMÉDIAT MAJEUR HCMV; ET (C) UN INTRON HÉTÉROLOGUE PRÉSENT À LA PLACE DE LA RÉGION D'INTRON A DU GÈNE PRÉCOCE IMMÉDIAT MAJEUR HCMV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64838205P | 2005-02-01 | 2005-02-01 | |
US67249705P | 2005-04-19 | 2005-04-19 | |
GBGB0507997.5A GB0507997D0 (en) | 2005-02-01 | 2005-04-20 | Nucleic acid constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29274B1 true MA29274B1 (fr) | 2008-02-01 |
Family
ID=36178086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30172A MA29274B1 (fr) | 2005-02-01 | 2007-08-28 | Constructions d'acide nucleique |
Country Status (20)
Country | Link |
---|---|
US (1) | US20100221349A1 (fr) |
EP (1) | EP1850869A2 (fr) |
JP (1) | JP2008528020A (fr) |
KR (1) | KR20070100403A (fr) |
CN (1) | CN101155597A (fr) |
AP (1) | AP2007004137A0 (fr) |
AU (1) | AU2006210716A1 (fr) |
BR (1) | BRPI0607119A2 (fr) |
CA (1) | CA2596731A1 (fr) |
EA (1) | EA011557B1 (fr) |
GB (1) | GB0507997D0 (fr) |
IL (1) | IL184653A0 (fr) |
MA (1) | MA29274B1 (fr) |
MX (1) | MX2007009164A (fr) |
NI (1) | NI200700191A (fr) |
NO (1) | NO20074421L (fr) |
SG (1) | SG158902A1 (fr) |
TN (1) | TNSN07295A1 (fr) |
WO (1) | WO2006082398A2 (fr) |
ZA (1) | ZA200707522B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ546554A (en) | 2003-10-10 | 2009-04-30 | Powderject Vaccines Inc | Nucleic acid constructs |
US20090220989A1 (en) * | 2005-12-05 | 2009-09-03 | Guava Technologies | Particle-Based Analyte Characterization |
EP1925318A1 (fr) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Vaccin à base de virus modifié de vaccin Ankara (MVA) recombinant contre la grippe aviaire |
US8778847B2 (en) | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
CA2715078C (fr) * | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Regions non traduites 5' (5'utr) synthetiques, vecteurs d'expression, et procedes pour augmenter l'expression transgenique |
JP5705545B2 (ja) * | 2007-11-12 | 2015-04-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | インフルエンザウイルスの複数のサブタイプに対する新規ワクチン |
WO2009092038A1 (fr) * | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vaccination a base d'adn de la grippe et methodes d'utilisation associees |
DK2358386T3 (en) | 2008-11-28 | 2017-02-13 | Statens Seruminstitut | Optimized flu vaccine |
US10022431B2 (en) | 2010-02-10 | 2018-07-17 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP2825693B1 (fr) * | 2012-03-15 | 2018-05-30 | Mayo Foundation For Medical Education And Research | Méthodes et matériaux de traitement du cancer |
CN103740715B (zh) * | 2013-12-25 | 2016-03-23 | 北京大北农科技集团股份有限公司 | 嵌合启动子及其用途 |
CN103901209B (zh) * | 2014-02-18 | 2016-05-25 | 王明丽 | 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒 |
US10188713B2 (en) | 2014-03-19 | 2019-01-29 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP3119426A4 (fr) | 2014-03-19 | 2018-02-28 | Mayo Foundation for Medical Education and Research | Méthodes et matériels pour le traitement du cancer |
CN105120042B (zh) * | 2015-09-09 | 2019-02-12 | 小米科技有限责任公司 | 移动终端 |
WO2017059902A1 (fr) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | Séquences utr 3' permettant la stabilisation d'arn |
US20210187064A1 (en) * | 2018-05-07 | 2021-06-24 | Administrators Of The Tulane Educational Fund | Mutated e. coli enterotoxins as anti-inflammatory agents |
WO2022155226A1 (fr) * | 2021-01-12 | 2022-07-21 | Duke University | Compositions et procédés pour la manipulation génétique du virus de la grippe |
WO2024097894A1 (fr) * | 2022-11-04 | 2024-05-10 | RNAimmune, Inc. | Compositions et procédés de vaccins à base d'acide ribonucléique codant nye-so-1 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3431140A1 (de) * | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5100792A (en) * | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5120657A (en) * | 1986-12-05 | 1992-06-09 | Agracetus, Inc. | Apparatus for genetic transformation |
US5204253A (en) * | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
TW360548B (en) * | 1993-04-08 | 1999-06-11 | Powderject Res Ltd | Products for therapeutic use |
DE69529495T2 (de) * | 1994-01-21 | 2003-06-12 | Powderject Vaccines Inc | Gasbetätigtes element zum austragen von genmaterial |
US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
WO2002031137A2 (fr) * | 2000-10-13 | 2002-04-18 | Chiron Corporation | Fragments d'intron a de cytomegalovirus |
DK1379273T3 (da) * | 2000-11-27 | 2009-11-09 | Powderject Vaccines Inc | Nukleinsyreadjuvanser |
GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
NZ546554A (en) * | 2003-10-10 | 2009-04-30 | Powderject Vaccines Inc | Nucleic acid constructs |
AU2004280630A1 (en) * | 2003-10-10 | 2005-04-21 | Powderject Vaccines, Inc. | Method |
-
2005
- 2005-04-20 GB GBGB0507997.5A patent/GB0507997D0/en not_active Ceased
-
2006
- 2006-02-01 SG SG201000360-6A patent/SG158902A1/en unknown
- 2006-02-01 KR KR1020077019899A patent/KR20070100403A/ko not_active Application Discontinuation
- 2006-02-01 CN CNA2006800110768A patent/CN101155597A/zh active Pending
- 2006-02-01 JP JP2007552730A patent/JP2008528020A/ja active Pending
- 2006-02-01 US US11/815,278 patent/US20100221349A1/en not_active Abandoned
- 2006-02-01 CA CA002596731A patent/CA2596731A1/fr not_active Abandoned
- 2006-02-01 BR BRPI0607119-8A patent/BRPI0607119A2/pt not_active IP Right Cessation
- 2006-02-01 MX MX2007009164A patent/MX2007009164A/es unknown
- 2006-02-01 WO PCT/GB2006/000344 patent/WO2006082398A2/fr active Application Filing
- 2006-02-01 EP EP06704134A patent/EP1850869A2/fr not_active Withdrawn
- 2006-02-01 AU AU2006210716A patent/AU2006210716A1/en not_active Abandoned
- 2006-02-01 EA EA200701643A patent/EA011557B1/ru not_active IP Right Cessation
- 2006-02-01 AP AP2007004137A patent/AP2007004137A0/xx unknown
-
2007
- 2007-07-17 IL IL184653A patent/IL184653A0/en unknown
- 2007-07-30 TN TNP2007000295A patent/TNSN07295A1/en unknown
- 2007-07-30 NI NI200700191A patent/NI200700191A/es unknown
- 2007-08-28 MA MA30172A patent/MA29274B1/fr unknown
- 2007-08-30 NO NO20074421A patent/NO20074421L/no not_active Application Discontinuation
- 2007-08-31 ZA ZA200707522A patent/ZA200707522B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
GB0507997D0 (en) | 2005-05-25 |
WO2006082398A3 (fr) | 2006-10-19 |
KR20070100403A (ko) | 2007-10-10 |
CN101155597A (zh) | 2008-04-02 |
MX2007009164A (es) | 2008-03-13 |
EA200701643A1 (ru) | 2008-02-28 |
US20100221349A1 (en) | 2010-09-02 |
TNSN07295A1 (en) | 2008-12-31 |
JP2008528020A (ja) | 2008-07-31 |
AU2006210716A1 (en) | 2006-08-10 |
SG158902A1 (en) | 2010-02-26 |
IL184653A0 (en) | 2007-12-03 |
NI200700191A (es) | 2008-02-05 |
EP1850869A2 (fr) | 2007-11-07 |
NO20074421L (no) | 2007-10-31 |
EA011557B1 (ru) | 2009-04-28 |
WO2006082398A2 (fr) | 2006-08-10 |
CA2596731A1 (fr) | 2006-08-10 |
BRPI0607119A2 (pt) | 2009-08-11 |
AP2007004137A0 (en) | 2007-08-31 |
ZA200707522B (en) | 2008-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29274B1 (fr) | Constructions d'acide nucleique | |
NO20062080L (no) | Nukleinsyrekonstrukter | |
MA32031B1 (fr) | Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf | |
MA29384B1 (fr) | Acides nucleiques de liaison a la ghreline | |
WO2006060630A3 (fr) | Dispositifs et procedes permettant de determiner l'activite d'une protease | |
WO2005086768A3 (fr) | Production amelioree de proteines fonctionnelles a partir de genes defectueux | |
WO2002038806A3 (fr) | Identification de polymorphismes d'acide nucleique | |
WO2005111220A3 (fr) | Vecteurs viraux adeno-associes avec des sequences palindromiques terminales heterologues intravectorielles | |
ATE541944T1 (de) | Polynukleotidprimer | |
MA30034B1 (fr) | Sirna anti myosine va et depigmentation de la peau | |
WO2006031955A3 (fr) | Procede de traitement faisant intervenir du bucindolol fonde sur le ciblage genetique | |
WO2004096842A3 (fr) | Sequences de nucleotides et d'acides amines du virus du sras, et utilisations associees | |
IL174195A0 (en) | Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes | |
WO2006032697A3 (fr) | Parvovirus | |
WO2007025989A3 (fr) | Variants d'acides nucleiques dans les genes recepteurs similaires a toll lies a une immunite innee alteree | |
DE602007010803D1 (de) | Befestigungswerkzeug für bewehrungsstab | |
EP1767653A4 (fr) | Sonde pour le diagnostic du syndrome de marfan et procédé de criblage avec la sonde | |
BR9907753A (pt) | Palheta de limpador | |
MXPA05008793A (es) | Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. | |
UA92913C2 (ru) | Экспрессионный вектор и способы продуцирования высоких уровней белков | |
WO2007023148A3 (fr) | Variants d'acides nucleiques dans le gene lbp associe a une immunite alteree innee | |
ATE533359T1 (de) | Peitsche, insbesondere doppelpeitsche, als teil einer schlachtlinie | |
WO2004070012A3 (fr) | Molecules d'elimination de cellules et methodes d'utilisation associees | |
NO20012415L (no) | Avstandsböyle for armering i forbindelse med muring, samt murverket som dannes | |
WO2005100386A3 (fr) | Récepteur de canine sensible au froid et au menthol 1 |